MedWatch

Genmab to raise USD 500 million and expand investor group in US offering

Genmab's upcoming IPO in the US is partly a way of involving more investors with insight in the biotech industry, says Senior Analyst in Sydbank, Søren Løntoft Hansen. But the offering will also reinforce the company's capital reserves that could potentially increase to approximately DKK 10 billion.

Foto: Tuala Hjarnø/Genmab

Last week, Danish biotech company Genmab proposed a public offering of its American Depositary Shares (ADSs) and applied for listing on Nasdaq in the US.

Genmab thus follows in the footsteps of another Danish company, Zealand Pharma, that carried out a similar IPO two years ago and is listed on Nasdaq in both Denmark and the US.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier